Form 13-F position report

BLACK DIAMOND THERAPEUTICS I

Reported by MORGAN STANLEY

BDTX CUSIP 09203E105 Manager CIK 0000895421

Reported 776,947 shares, up 545,747 (236.0%) from the prior quarter.

Reported value 242.4%; share count 236.0% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 776,947 Quarter-end amount reported
Reported value $1,464,545 Fair value at quarter end
Consecutive quarters held 27 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 4126000
2022-03-31 1365000
2022-06-30 1317000
2022-09-30 387000
2022-12-31 56164
2023-03-31 52871
2023-06-30 82158
2023-09-30 63286
2023-12-31 33245
2024-03-31 298613
2024-06-30 1008088
2024-09-30 543767
2024-12-31 466563
2025-03-31 657758
2025-06-30 223989
2025-09-30 262033
2025-12-31 231213
2026-03-31 188767
2026-06-30 427720
2026-09-30 1464545

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for BLACK DIAMOND THERAPEUTICS I held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 776,947 +545,747 (236.0%) < 0.01% $1,464,545 2026-11-13
Q2 2026 Added 231,200 +142,577 (160.9%) < 0.01% $427,720 2026-08-13
Q1 2026 Reduced 88,623 -6,526 (-6.9%) < 0.01% $188,767 2026-05-15
Q4 2025 Added 95,149 +26,011 (37.6%) < 0.01% $231,213 2026-02-13
Q3 2025 Reduced 69,138 -21,180 (-23.5%) < 0.01% $262,033 2025-11-14
Q2 2025 Reduced 90,318 -334,042 (-78.7%) < 0.01% $223,989 2025-08-15
Q1 2025 Added 424,360 +206,340 (94.6%) < 0.01% $657,758 2025-05-15
Q4 2024 Added 218,020 +93,016 (74.4%) < 0.01% $466,563 2025-02-14
Q3 2024 Reduced 125,004 -91,324 (-42.2%) < 0.01% $543,767 2024-11-14
Q2 2024 Added 216,328 +157,430 (267.3%) < 0.01% $1,008,088 2024-08-14
Q1 2024 Added 58,898 +47,067 (397.8%) < 0.01% $298,613 2024-05-15
Q4 2023 Reduced 11,831 -10,220 (-46.3%) < 0.01% $33,245 2024-02-13
Q3 2023 Added 22,051 +5,782 (35.5%) < 0.01% $63,286 2023-11-15
Q2 2023 Reduced 16,269 -11,705 (-41.8%) < 0.01% $82,158 2023-08-14
Q1 2023 Reduced 27,974 -3,228 (-10.3%) < 0.01% $52,871 2023-05-15
Q4 2022 Reduced 31,202 -197,987 (-86.4%) < 0.01% $56,164 2023-02-14
Q3 2022 Reduced 229,189 -306,202 (-57.2%) < 0.01% $387,000 2022-11-14
Q2 2022 Added 535,391 +42,523 (8.6%) < 0.01% $1,317,000 2022-08-15
Q1 2022 Reduced 492,868 -280,968 (-36.3%) < 0.01% $1,365,000 2022-05-13
Q4 2021 Added 773,836 +13,034 (1.7%) < 0.01% $4,126,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

122 managers reported BLACK DIAMOND THERAPEUTICS I for Q3 2026.

Managers reporting BLACK DIAMOND THERAPEUTICS I in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
NEA Management Company LLC Unchanged 4,448,757 0 0.61% $8,385,907 27 qtrs
BlackRock Inc Added 4,300,642 +383,554 < 0.01% $8,106,711 9 qtrs
T Rowe Price Investment Management Inc Reduced 3,925,698 -102,504 < 0.01% $7,400,000 13 qtrs
ACADIAN ASSET MANAGEMENT LLC Unchanged 2,348,651 0 < 0.01% $4,420,000 8 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Unchanged 2,125,270 0 < 0.01% $4,006,134 3 qtrs
Bank of America Corporation Added 2,047,829 +1,634,313 < 0.01% $3,860,159 27 qtrs
Defilade Capital Management L P Added 1,770,948 +95,949 0.56% $3,338,237 2 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 1,652,100 -310,294 < 0.01% $3,114,209 20 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 1,246,314 +28,143 < 0.01% $2,350,129 27 qtrs
MARSHALL WACE LLP Added 1,176,357 +279,755 < 0.01% $2,223,316 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
763,196
Shared
0
None
13,751

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.